Maxcyte (MXCT) Cash & Equivalents (2020 - 2026)

Maxcyte (MXCT) has reported Cash & Equivalents for 7 consecutive years, with $15.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 1.2% year-over-year to $15.0 million in Q2 2026; TTM through Jun 2026 was $15.0 million, a 1.2% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, down 28.04% from the prior year.
• Cash & Equivalents was $15.0 million for Q2 2026 at Maxcyte, up from $14.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $239.8 million in Q1 2022 and troughed at $11.1 million in Q4 2022.
• A 5-year average of $45.4 million and a median of $32.4 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 320.3% in 2023, down 84.22% in 2023.
• Over 5 years, Cash & Equivalents stood at $11.1 million in 2022, then jumped by 320.3% to $46.5 million in 2023, then slumped by 40.04% to $27.9 million in 2024, then decreased by 28.04% to $20.1 million in 2025, then retreated by 25.03% to $15.0 million in 2026.
• The last three Cash & Equivalents figures came in at $15.0 million (Q2 2026), $14.6 million (Q1 2026), and $20.1 million (Q4 2025), per Business Quant data.